Vancomycin resistant enterococcus risk factors for hospital colonization in hematological patients: a matched case-control study.
Hematological
Risk factors
Vancomycin resistant Enterococcus
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
13 11 2023
13 11 2023
Historique:
received:
23
07
2023
accepted:
05
11
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Vancomycin-resistant enterococcus (VRE) was the fastest growing pathogen in Europe in 2022 (+ 21%) but its clinical relevance is still unclear. We aim to identify risk factors for acquired VRE rectal colonization in hematological patients and evaluate the clinical impact of VRE colonization on subsequent infection, and 30- and 90-day overall mortality rates, compared to a matched control group. A retrospective, single center, case-control matched study (ratio 1:1) was conducted in a hematological department from January 2017 to December 2020. Case patients with nosocomial isolation of VRE from rectal swab screening (≥ 48 h) were matched to controls by age, sex, ethnicity, and hematologic disease. Univariate and multivariate logistic regression compared risk factors for colonization. A total of 83 cases were matched with 83 controls. Risk factors for VRE colonization were febrile neutropenia, bone marrow transplant, central venous catheter, bedsores, reduced mobility, altered bowel habits, cachexia, previous hospitalization and antibiotic treatments before and during hospitalization. VRE bacteraemia and Clostridioides difficile infection (CDI) occurred more frequently among cases without any impact on 30 and 90-days overall mortality. Vancomycin administration and altered bowel habits were the only independent risk factors for VRE colonization at multivariate analysis (OR: 3.53 and 3.1; respectively). Antimicrobial stewardship strategies to reduce inappropriate Gram-positive coverage in hematological patients is urgently required, as independent risk factors for VRE nosocomial colonization identified in this study include any use of vancomycin and altered bowel habits. VRE colonization and infection did not influence 30- and 90-day mortality. There was a strong correlation between CDI and VRE, which deserves further investigation to target new therapeutic approaches.
Sections du résumé
BACKGROUND
Vancomycin-resistant enterococcus (VRE) was the fastest growing pathogen in Europe in 2022 (+ 21%) but its clinical relevance is still unclear. We aim to identify risk factors for acquired VRE rectal colonization in hematological patients and evaluate the clinical impact of VRE colonization on subsequent infection, and 30- and 90-day overall mortality rates, compared to a matched control group.
METHODS
A retrospective, single center, case-control matched study (ratio 1:1) was conducted in a hematological department from January 2017 to December 2020. Case patients with nosocomial isolation of VRE from rectal swab screening (≥ 48 h) were matched to controls by age, sex, ethnicity, and hematologic disease. Univariate and multivariate logistic regression compared risk factors for colonization.
RESULTS
A total of 83 cases were matched with 83 controls. Risk factors for VRE colonization were febrile neutropenia, bone marrow transplant, central venous catheter, bedsores, reduced mobility, altered bowel habits, cachexia, previous hospitalization and antibiotic treatments before and during hospitalization. VRE bacteraemia and Clostridioides difficile infection (CDI) occurred more frequently among cases without any impact on 30 and 90-days overall mortality. Vancomycin administration and altered bowel habits were the only independent risk factors for VRE colonization at multivariate analysis (OR: 3.53 and 3.1; respectively).
CONCLUSIONS
Antimicrobial stewardship strategies to reduce inappropriate Gram-positive coverage in hematological patients is urgently required, as independent risk factors for VRE nosocomial colonization identified in this study include any use of vancomycin and altered bowel habits. VRE colonization and infection did not influence 30- and 90-day mortality. There was a strong correlation between CDI and VRE, which deserves further investigation to target new therapeutic approaches.
Identifiants
pubmed: 37957773
doi: 10.1186/s13756-023-01332-x
pii: 10.1186/s13756-023-01332-x
pmc: PMC10644555
doi:
Substances chimiques
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
126Informations de copyright
© 2023. The Author(s).
Références
Int J Hematol Oncol Stem Cell Res. 2022 Jul 1;16(3):164-173
pubmed: 36694706
Antibiotics (Basel). 2021 Jul 23;10(8):
pubmed: 34438947
Antimicrob Resist Infect Control. 2014 Dec 01;3(1):37
pubmed: 25671098
Clin Infect Dis. 2020 Jul 27;71(3):645-651
pubmed: 31504328
Transpl Infect Dis. 2013 Oct;15(5):466-73
pubmed: 23911080
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S54-S62
pubmed: 30895215
Antimicrob Resist Infect Control. 2018 Nov 14;7:133
pubmed: 30459945
Leuk Res. 2020 Dec;99:106463
pubmed: 33130331
Hematol Oncol Clin North Am. 2017 Dec;31(6):981-993
pubmed: 29078933
J Clin Microbiol. 2016 Oct;54(10):2436-47
pubmed: 27147728
Antibiotics (Basel). 2021 Jan 22;10(2):
pubmed: 33499102
Am J Infect Control. 2017 Mar 1;45(3):260-266
pubmed: 27852447
Clin Infect Dis. 2000 Oct;31(4):1058-65
pubmed: 11049790
Eur J Haematol. 2007 Sep;79(3):226-33
pubmed: 17655696
J Neurogastroenterol Motil. 2021 Jan 30;27(1):19-34
pubmed: 33166939
Clin Infect Dis. 2012 Aug;55 Suppl 2:S121-6
pubmed: 22752860
Antimicrob Agents Chemother. 2002 Jun;46(6):1619-28
pubmed: 12019066
Biol Blood Marrow Transplant. 2007 May;13(5):615-21
pubmed: 17448922
Clin Infect Dis. 2011 Feb 15;52(4):e56-93
pubmed: 21258094
Antimicrob Resist Infect Control. 2020 Jan 31;9(1):22
pubmed: 32005223
Leuk Lymphoma. 2014 Jun;55(6):1320-5
pubmed: 24024476
Infect Control Hosp Epidemiol. 2015 Jan;36(1):47-53
pubmed: 25627761
Nature. 2022 Nov;611(7937):780-786
pubmed: 36385534
Infect Genet Evol. 2020 Nov;85:104519
pubmed: 32877660
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31405857
J Infect Dis. 2005 Feb 15;191(4):588-95
pubmed: 15655783
Ann Hematol. 2021 Jan;100(1):239-259
pubmed: 32997191
Biol Blood Marrow Transplant. 2017 Feb;23(2):340-346
pubmed: 27890428
Saudi J Biol Sci. 2021 May;28(5):2895-2899
pubmed: 34012328
N Engl J Med. 2022 Jan 20;386(3):220-229
pubmed: 35045228
BMC Infect Dis. 2020 Mar 18;20(1):228
pubmed: 32188401
J Glob Antimicrob Resist. 2021 Mar;24:198-204
pubmed: 33359937
Am J Infect Control. 2020 Mar;48(3):324-326
pubmed: 31551123
Am J Transplant. 2014 Aug;14(8):1887-94
pubmed: 25040438
Curr Opin Infect Dis. 2013 Aug;26(4):338-44
pubmed: 23743816
Int J Infect Dis. 2014 Sep;26:76-82
pubmed: 24813873
Infect Control Hosp Epidemiol. 2016 Jan;37(1):26-35
pubmed: 26434609
CA Cancer J Clin. 2023 Mar;73(2):147-163
pubmed: 36149820
Biol Blood Marrow Transplant. 2019 Mar;25(3):594-598
pubmed: 30448456
Clin Infect Dis. 2019 Oct 30;69(10):1771-1779
pubmed: 30649224
J Antimicrob Chemother. 2018 Jun 1;73(6):1692-1699
pubmed: 29548009
Antimicrob Resist Infect Control. 2018 Aug 23;7:103
pubmed: 30155243
Open Forum Infect Dis. 2016 Dec 07;4(1):ofw246
pubmed: 28480243
Infect Drug Resist. 2015 Jul 24;8:217-30
pubmed: 26244026
Antimicrob Resist Infect Control. 2020 Aug 10;9(1):130
pubmed: 32778149
Clin Microbiol Infect. 2008 Jan;14(1):14-21
pubmed: 18005178
Infect Control Hosp Epidemiol. 2013 Jan;34(1):69-73
pubmed: 23221195
Clin Infect Dis. 2017 Jun 15;64(12):1753-1759
pubmed: 28369204
Indian J Hematol Blood Transfus. 2015 Mar;31(1):51-6
pubmed: 25548445
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S25-34
pubmed: 16323116